Market: median 1d +0.0% · breadth 45.0% advancing across 191 names
Data as of — announcements 2026-08-21 · prices 2026-08-20
New today: AON, ILA, MQR, SQX. New names versus yesterday's letter, so a continuing story doesn't read as fresh news.
Read these (4)
Today's announcements worth minutes, not seconds — triaged by deterministic rules (a raise, a result into live flow, quantified materiality). The LLM annotates; it never picks the bucket.
Administrative Court in Toulouse rejected an NGO challenge to France's DGEC authorization for Couflens, removing a material permitting obstacle for this strategically important tungsten asset. AON can now resume exploration, though a 15-day appeal window remains.
💰Couflens project: Tungsten deposit, France · Administrative Court ruling: NGO application rejected; interim suspension voided · Appeal window: 15 days for Group to appeal · Cash position: $7.7m
Materiality: Regulatory de-risking of flagship tungsten project; removal of suspension directly unblocks $7.7m cash runway for exploration advancement.
Priced in? Stock +21% over 5d suggests market anticipated favorable court outcome; volume spike (2.2×) and institutional inflow (+$5k) indicate confirmation trade into pre-positioned longs.
🚀 EXTENDED · RSI 89 · 5d +21.3%confidence: high
high-confidence read, materiality quantified
ILA — Island boosts Galidesivir supply as Ebola surges
Island is executing a deliberate biodefence strategy by securing a substantial GMP-grade Galidesivir inventory (700–800 courses by Q4 2026) ahead of active deployment in Uganda, where the rapidly accelerating Bundibugyo Ebola outbreak (5,208 cases, 47.5% CFR) creates both an urgent need and a human data generation opportunity. The move reduces the company's manufacturing cycle dependency and positions it for government/biodefence agency engagement without waiting for pivotal trial data.
💰Galidesivir inventory target: 700–800 treatment courses by Q4 2026 · Bundibugyo outbreak severity: 5,208 confirmed cases, 2,476 deaths, 47.5% CFR as of 18 Aug 2026 · Outbreak spread rate: 5× faster than historical pace at equivalent stage · Manufacturing partner: PI Health Sciences (PIHS)
Materiality: Manufacturing investment quantum not disclosed; inventory of 700–800 courses represents operational optionality and potential near-term deployment pathway, but cash position ($12.9m) suggests this is likely funded from existing facilities or third-party arrangements. Material in regulatory/strategic terms, not immediately balance-sheet material.
Priced in? Stock flat over 5d and +10% over 20d into the announcement; no material run-up immediately preceding; this represents confirmation of strategy articulated in prior MEURI approval (7 July) and initial manufacturing commissioning (4 June), so incremental positioning rather than surprise.
🚀 EXTENDED · RSI 72 · 5d +0.0%confidence: high
high-confidence read, materiality quantified
MQR · $5M — WEST SPARGOVILLE PROGRAM REFINES SPODUMENE PEGMATITE TARGETS
MQR has completed field mapping and rock-chip sampling (49 samples pending assay) at West Spargoville to refine pegmatite geometry; the key insight is that historical RC drilling was geometrically oblique to the now-interpreted steep northwest-dipping pegmatite trends, meaning prior holes may have under-tested zones previously returning up to 3.01% Li2O surface grades. The refined 3D model will guide a re-oriented drill program targeting higher-priority pegmatite trends.
💰Rock-chip samples collected: 49 · Previous peak Li2O grade: 3.01% · Target area size: 1.5 km × 1.5 km · Pegmatite strike orientation: Northeast-southwest
Materiality: No new assays reported; program is pre-assay stage with ~$5m market cap. Field/structural refinement de-risks next drilling phase but magnitude of impact depends on pending ALS results and subsequent drill outcomes—insufficient quantified materiality at this stage.
Priced in? Stock +25% over 20 days but flat over 5 days; modest retail/MM inflows (~$74k) suggest incremental interest but no major accumulation ahead of this announcement—largely a technical de-risking update with upside contingent on lab results.
🚀 EXTENDED · RSI 75 · 5d +0.0%confidence: medium
🏔 near SGQ.AX ($423M — 81.71× subject cap) · near GL1.AX ($194M — 37.5× subject cap) · near MIN.AX ($13.0B major in district)
SQX is raising ~$2.5m via fully underwritten non-renounceable entitlement offer at $0.04/share to shore up balance sheet, with directors sub-underwriting $130k. The company remains in capital-constrained exploration mode with no material near-term news flow.
💰Raise amount: $2.468m (before costs) · Issue price: $0.04 per share · New shares: 61.7m · Entitlement ratio: 2 for 3
Materiality: Raise ~50% of current $5m market cap; if successful, dilutes existing holders by 40% (2-for-3 basis).
Priced in? Stock +5% over 5d but -2% over 20d; modest pre-announcement uptick suggests limited prior leak; market reaction pending subscription rates.
🚀 EXTENDED · RSI 75 · 5d +5.5%confidence: high
high-confidence read, materiality quantified
Also worth a skim (4)
Price-sensitive but routine — quarterlies and updates worth a headline-level pass.
AT4 — Del Sol Hydromet Refinery Operational Update · quantified but moderate — skim
NPM — Trading Halt · quantified but moderate — skim
PNN — Trading Halt · quantified but moderate — skim
TMX — 7 New Priority IP Gold Drill Targets Defined at Smokebush · quantified but moderate — skim
Pattern tracker
The pre-registered quiet pattern, tallied out-of-sample since 2026-07-03 — every hit counted in public, wins and losses. Small n, on purpose.
The registered quiet-accumulation pattern, tracked out-of-sample since 2026-07-03. The current rule definition and the full scored record live on the track record— the page never restates the rule, so the two can't drift.
1
new today
36
resolved
56%
win rate
n=36, median 5d +6.7%. Out-of-sample receipt only — not a backtest.